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Background. To interpret cervical cancer screening model results, we need to understand the influence of model
structure and assumptions on cancer incidence and mortality predictions. Cervical cancer cases and deaths following
screening can be attributed to 1) (precancerous or cancerous) disease that occurred after screening, 2) disease that
was present but not screen detected, or 3) disease that was screen detected but not successfully treated. We examined
the relative contributions of each of these using 4 Cancer Intervention and Surveillance Modeling Network
(CISNET) models. Methods. The maximum clinical incidence reduction (MCLIR) method compares changes in the
number of clinically detected cervical cancers and mortality among 4 scenarios: 1) no screening, 2) one-time perfect
screening at age 45 that detects all existing disease and delivers perfect (i.e., 100% effective) treatment of all screen-
detected disease, 3) one-time realistic-sensitivity cytological screening and perfect treatment of all screen-detected dis-
ease, and 4) one-time realistic-sensitivity cytological screening and realistic-effectiveness treatment of all screen-
detected disease. Results. Predicted incidence reductions ranged from 55% to 74%, and mortality reduction ranged
from 56% to 62% within 15 years of follow-up for scenario 4 across models. The proportion of deaths due to disease
not detected by screening differed across the models (21%–35%), as did the failure of treatment (8%–16%) and dis-
ease occurring after screening (from 1%–6%). Conclusions. The MCLIR approach aids in the interpretation of varia-
bility across model results. We showed that the reasons why screening failed to prevent cancers and deaths differed
between the models. This likely reflects uncertainty about unobservable model inputs and structures; the impact of
this uncertainty on policy conclusions should be examined via comparing findings from different well-calibrated and
validated model platforms.
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Microsimulation models are increasingly being used to
estimate the long-term population effects of cervical can-
cer screening programs. Collaborative modeling can
enhance the rigor of modeling research through the use
of multiple independent models, with standardized
model inputs, to answer the same research or policy
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questions. The US National Cancer Institute–funded
Cancer Intervention and Surveillance Modeling Network
(CISNET) was established in 2000 to use collaborative
modeling to improve our understanding of the impact of
cancer prevention, screening, and treatment dissemina-
tion on population trends in cancer incidence and mor-
tality.1 The CISNET Cervical Cancer Working Group
started in 2015 and includes 5 modeling teams. Prior to
CISNET, each model was independently developed for 3
different countries (i.e., the United States, Australia, and
the Netherlands) and is unique in its structure, assump-
tions, and methods of synthesizing data. Consequently,
they are unique in how they project the impact of screen-
ing and treatment on cervical cancer incidence and mortal-
ity. Results that are similar across multiple models, despite
differences in assumptions and modeling approach,
enhance the credibility of the findings and are more likely
to be robust than conclusions obtained from a single
model; results that are different across models reveal areas
of uncertainty and priorities for future research.
While country-specific factors (e.g., cost-effectiveness
thresholds, disease burden) may contribute to relevant
variations in policy conclusions, it is important to under-
stand how different model structures and combinations
of assumptions contribute to these differences. Detailed
model descriptions are necessary and contribute to model
transparency. Although all inputs of a model should
always be reported, assumptions on natural history para-
meters, such as the dwell time (i.e., the period in which
the asymptomatic disease could be caught by screening)
and their implications, remain difficult to assess even
with comprehensive documentation.
In the absence of screening, cervical cancers will only
be diagnosed as a result of clinical symptoms (i.e., clini-
cal incidence). Clinical incident cancer cases and cancer-
specific deaths that occur after screening have 3 possible
origins: 1) the disease was not present at the time of
screening, 2) the disease was present but not detected by
screening (i.e., limitations in test sensitivity), or 3) precli-
nical disease (precancerous lesions and preclinical can-
cers) was not completely removed or recurrence of that
lesion occurred. The maximum clinical incidence reduc-
tion (MCLIR) method can be used to examine and dis-
entangle the relative contributions of these 3 origins of
different screening models. The MCLIR method is able
to isolate the unobservable effects of lesion onset and
duration, screening test sensitivity, and precancerous
lesions and cancer treatment by comparing model results
before and after imposing a one-time screening interven-
tion under varying assumptions about screening perfor-
mance and treatment effectiveness. These effects are
unobservable because of limited knowledge of underly-
ing natural history processes and parameters, and they
include parameters for which traditional epidemiologic
studies would be impossible or unethical to conduct.
Previously, the MCLIR method has been applied to 3
CISNET colorectal2 and 6 breast cancer3 models to
delineate the effects of natural history assumptions and
model structure on colorectal and breast cancer predic-
tions. In this study, we applied the MCLIR method to
understand how differences among the CISNET cervical
cancer models affect predictions for screening effective-
ness by projecting the clinical incidence and mortality
reductions after a one-time screening test at age 45 years
among women without prior screening. The results are
intended to provide a greater understanding of how the
CISNET cervical models depict unobservable processes
(such as the progression of underlying disease and the
missed detection of existing disease) and how those
representations may systematically affect conclusions
about screening impact on incidence and mortality.
Methods
We used 4 well-established CISNET-Cervical microsimu-
lation models (Harvard,4 Microsimulation Screening
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Analysis [MISCAN]–Cervix,5 Policy1-Cervix [CCNSW],6
and University of Minnesota [UMN]–HPV Cancer
[CA]7) to project outcomes for a hypothetical cohort of
individual women. This analysis was conducted prior to
standardization of each model to the US population and
screening performance.
Each of the 4 CISNET-Cervical models simulates the
underlying natural history of human papillomavirus
(HPV)–induced cervical cancer but differs with respect
to the type and number of health states, HPV genotypes
included, cycle length, and data sources used to parame-
terize the baseline model prior to model fitting (i.e., cali-
bration) to the observed data (Box). In general, all 4
models simulate a large study population with individual
life histories, in which women can acquire HPV infections,
develop precancerous lesions, and, in some cases, develop
cervical cancer. Death can occur from background causes
or cervical cancer among those with disease. Infections
can clear or progress to cervical intraepithelial lesions that
may regress. Women can acquire multiple infections dur-
ing a lifetime, each with its own clinical course. The mod-
els produce age-specific outputs of disease incidence and
mortality over time. Screening can affect the life histories of
individual women. These changes constitute the effects of the
intervention and are represented by the numbers of events
and the stage of cancer that is detected or prevented.
Standardized profiles of each model’s structure and
underlying model parameters and assumptions, with
additional references, are available at http://cisnet.can
cer.gov/profiles/. Additional model specifications and
key parameters are provided in Table 1.
MCLIR Analysis
To illustrate the effects of model structure and assump-
tions about lesion development, lesion progression,
screening test ability to detect lesions, and precancerous
lesion treatment on cervical cancer incidence and mortal-
ity predictions, the MCLIR analysis consists of compari-
sons between 4 scenarios. Three scenarios involve a one-
time screening test at age 45 years, and the remaining sce-
nario of no screening serves as a comparator. The study
population for each scenario is a cohort of average-risk
women born in 1980 who have never been screened or
diagnosed with cervical cancer prior to age 45 years. Age
45 years was selected to illustrate model differences
because it is in the middle of the start and stop ages of
recommended screening guidelines,8 and there is suffi-
ciently high incidence of cervical cancer at this age to
illustrate model differences. Women were followed for 5
years (i.e., up to age 50) and 15 years (i.e., up to age 60)
to capture the short- and longer-term effects of the
intervention. Model outcomes included cervical cancer
incidence and mortality by age.
MCLIR Scenarios
To disentangle the impacts of the 3 possible sources of
residual cancer following one-time screening, the
MCLIR method compares changes in the number of
clinically detected cervical cancer cases and deaths
between 4 simplified scenarios (Figure 1): 1) no-screen-
ing; 2) one-time perfect cervical screening at age 45 years,
which detects all existing precancerous lesions and
assumes perfect treatment of all screen-detected lesions
(i.e., lesion completely removed and no recurrent dis-
ease); 3) one-time realistic-sensitivity cytological screen-
ing at age 45 years, which assumes imperfect detection of
precancerous lesions and perfect treatment of all screen-
detected lesions; and 4) one-time realistic-sensitivity
cytological screening at age 45 years and realistic-
effectiveness treatment of all screen-detected lesions.
Assumptions for realistic cytological screening and rea-
listic treatment of all screen-detected lesions differed
between the models (Table 1).
We calculated the attributable fraction (i.e., origin) of
cervical cancer incident cases and deaths in the 4
CISNET models, 5 years and 15 years after screening at
age 45 years. We did this by dividing the difference in
number of cancers/deaths between the different mod-
eled scenarios (see Figure 1) with the number of can-
cers in the no-screening scenario. Because in some
models, women were not all screened exactly on their
45th birthday but within the 45th year of life, we
excluded the first follow-up year when calculating the
attributional fractions.
Results
Figure 2 shows how the attributable fractions (Table 2)
are calculated, using cervical cancer mortality in the
Harvard model as an example.
Incidence Reduction Predictions
Short-term (5-year) effects of screening. When we
assumed realistic screening at age 45 years, we found that
after 5 years, the proportion of cancer cases prevented
differed between the models, ranging from 65% to 81%
(Table 2). The short-term differences in prevented clini-
cal cancer cases were primarily caused by differences in
assumed test sensitivity; for example, 19% of the preva-
lent lesions that caused cancer within 5 years were not
detected in the Policy1-Cervix model, compared to 26%
de Kok et al. 3
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in MISCAN, 27% in the UMN-HPV CA model, and
32% in the Harvard model.
Long-term (15-year) effects of screening. After 15 years,
the proportion of cancer cases prevented ranged from
55% to 74% across the models (Table 2). The long-term
differences in the percentages of prevented cancer cases
were caused by differences in all 3 possible sources of
residual cancer following one-time screening: the lesion
that caused cancer prior to age 60 years was not present
at age 45 years in 12% of the cases in the UMN-HPV CA
model, compared to 6% in MISCAN, 4% in the Policy1-
Cervix, and 2% in the Harvard model. Furthermore, the
percentage of the lesions present, but not detected, ranged
from 22% to 38%. In the Harvard model, 5% of the pre-
cancerous lesions that were detected at age 45 years were
Table 1 Assumptions for Realistic Cytological Screening and Realistic Treatment in the 4 Models
Model Parameter
Assumptions, %
Harvard MISCAN Policy1-Cervix UMN-HPV CA
Test probability of at least ASC-US for
CIN grade 1 NA 40 39.4 NA
CIN grade 2 70.0 50 64.9 72.7
CIN grade 3 or worse 70.0 75 83.9 72.7
Test probability of at least HSIL for
CIN grade 1 NA 4 3.0 NA
CIN grade 2 17.5 18 22.5
CIN grade 3 45.5 56 35.0
Cervical cancer 53.9 60 35.0
Specificity (CIN grade 1 or worse)a 91.0 97.6 96.2 91.9
Cure rate precancerous lesions 100 100 93.6b 100
10-year age-specific probability that clinical cervical cancer will lead to death (100%—10-year survival)c
Local
0 5.7 9.7 21.3 4.4
30 5.3 9.7 21.3 4.4
45 8.3 10.8 21.3 9.4
60 13.3 22.9 21.3 31.2
80 39.0 34.5 21.3 31.2
100 39.0 34.5 21.3 31.2
Regional
0 42.9 45.5 46.7 49.8
30 38.7 45.5 46.7 49.8
45 38.0 51.1 46.7 58.9
60 43.9 55.4 46.7 70.3
80 66.7 68.7 46.7 70.3
100 66.7 68.7 46.7 70.3
Distant
0 86.6 45.5 81.0 71.6
30 77.6 45.5 81.0 71.6
45 79.5 51.1 81.0 73.5
60 81.2 55.4 81.0 88.2
80 94.7 68.7 81.0 88.2
100 94.7 68.7 81.0 88.2
Reduction of the risk of dying of cervical cancer after screen-detected cancer per cancer stage
Micro invasive NA 89.4 NA NA
Local NA 50 15 NA
Regional/distant NA 20 0 NA
ASC-US, atypical squamous cells of undetermined significance; CIN, cervical intraepithelial neoplasia; HSIL, high-grade squamous
intraepithelial lesion; NA, not applicable.
aCIN grade 2 or worse for the Harvard and UMN-HPV CA models, since they do not model CIN grade 1.
bRecurrence in women treated for precancerous lesions is modeled explicitly with a different natural history.
cFor the Harvard model, these are the 5-year probabilities of dying applied in the first 12 months for squamous cell carcinoma, after which,
survival improves with time since diagnosis through year 20. No excess mortality is assumed after 20 years of survival.
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not treated effectively and caused cancer before the age of
60 (compared to 0% in the other models).
Screening effects over time. The proportion of clinical
cancer cases prevented by realistic screening after age 45
years decreased after the screening age in all models
(Figure 3). The difference between the models in the
reduction of cancer as a result of screening was stable
over time.
Mortality Reduction Predictions
Short-term (5-year) effects of screening. After 5 years,
the proportion of deaths prevented by screening in each
model ranged from 42% to 59% (Table 2). This difference
was primarily caused by differences in the effectiveness of
treatment (or probability of recurrent disease) of detected
lesions (proportion of deaths ranging from 38% to 10%).
Long-term (15-year) effects of screening. After 15 years,
the proportion of deaths prevented by screening in each
model was comparable and ranged from 56% to 62%
(Table 2). In all models, the most important contributor
to cancer death after screening was imperfect test sensitiv-
ity: in the Harvard model, of the lesions that were present
at age 45 years and resulted in a cervical cancer death
before age 60 years, 35% were not detected with screening
at age 45 years, compared to 21% in the Policy1-Cervix
model, 27% in MISCAN, and 26% in the UMN-HPV
CA model. Of the detected lesions that resulted in a cervi-
cal cancer death before age 60 years, 16% could not be
Figure 1 A schematic presentation how the impact of 3 contributors to cancer (mortality) after screening can be disentangled
with modeling.
Figure 2 Illustrative example using the Harvard model:
cervical cancer mortality rate, divided by explanation
(‘‘contributor’’) of the mortality, after 1 screening round at age
45 years. Each area in the graph represents a comparison
between numbers of cancer deaths in one scenario v. another
scenario (see Figure 1). The colors of the graph match the
colors of the ‘‘women’’ in Figure 1, and the percentages refer
to the attributional fractions presented in Table 2 (mortality in
the Harvard model after 15 years of follow-up). The dark gray
area (‘‘cancer deaths prevented’’; i.e., the difference between
‘‘no screening’’ and ‘‘realistic sensitivity and treatment’’) is the
screening effect (Figure 3 and Table 3).
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successfully treated (or recurrent disease occurred) in the
Policy1-Cervix model, compared to only 8% in MISCAN
and Harvard and 7% in UMN-HPV CA.
Screening effects over time. The proportion of cancer
deaths prevented by realistic screening after age 45 years
increased rapidly after the screening age in all models
(Figure 3); however, in the Harvard model, the maximum
preventable proportion was reached more rapidly (after
approximately 3 years) compared to the other models
(approximately 10 years for UMN-HPV CA, 9 years for
Policy1-Cervix, and 5 years for MISCAN). As a result,
the attributable fractions of cervical cancer death for the
different origins vary in time between the 4 different
CISNET models (Table 2).
Discussion
This study is the first to apply the MCLIR method
to illustrate how model structure and assumptions affect
cervical cancer incidence and mortality predictions.
To understand variations in model estimates of screening
effects, the analysis decomposed the relative contributions
of model-specific structures and assumptions regarding the
preclinical duration of cervical lesions, the ability of a
screening test to detect lesions, and the role of treatment
of cervical lesions and their subsequent recurrence after
treatment as contributors to cervical cancer incidence and
mortality predictions.
The independently developed models showed similar
long-term reductions in cervical cancer incidence and
mortality after a one-time screening test at age 45 years.
We found that these reductions were primarily caused by
the probability of detecting a present lesion and by the
effectiveness of treatment of detected lesions, although
the attributional fraction of the 2 was different across the
4 models. Differences across models in the probability to
detect a lesion can be explained by the sensitivity of the
screening test per health state (which ranges from 70.0%
for cervical intraepithelial neoplasia type 3 or worse in
the Harvard model, compared to 83.9% in Policy1-
Cervix, for example) but also by the prevalence of the dif-
ferent health states at the time of screening. The latter
can differ across models because of differences in natural
history assumptions. The fraction of cancer cases (and
deaths) that occurred within 15 years after screening (i.e.,
Table 2 Attributable Fraction of Cervical Cancer Incident Cases and Deaths by Modela
Origin
Harvard,
%
MISCAN,
%
Policy1-Cervix,
%
UMN-HPV
CA, %
Incidence
5 years of follow-up
Lesion not present 0 0 0 2
Lesion present but not detected 32 26 19 28
Lesion detected but not effectively treated (or recurrent disease) 3 0 0 0
Cancer cases prevented by screening 65 74 81 70
15 years of follow-up
Lesion not present 2 6 4 12
Lesion present but not detected 38 27 22 25
Lesion detected but not effectively treated (or recurrent disease) 5 0 0 0
Cancer cases prevented by screening 55 66 74 63
Mortality
5 years of follow-up
Lesion not present 0 0 0 0
Lesion present but not detected 31 25 20 29
Lesion detected but not effectively treated (or recurrent disease) 10 20 38 17
Cancer deaths prevented by screening 59 55 42 53
15 years of follow-up
Lesion not present 1 3 2 6
Lesion present but not detected 35 27 21 27
Lesion detected but not effectively treated (or recurrent disease) 8 8 16 7
Cancer deaths prevented by screening 56 62 61 60
aAttributable fraction (i.e., origin) of cervical cancer incident cases and deaths that occur 15 years and 5 years after screening at age 45 years in
the 4 Cancer Intervention and Surveillance Modeling Network models. Each fraction represents the difference between 2 modeled scenarios (see
Figure 1); the percentage cancer cases/deaths prevented is the difference between the ‘‘realistic sensitivity and treatment’’ scenario and ‘‘no
screening.’’
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were not yet present at the time of screening) also differed
across the models (from 2% to 12%). This difference can
be explained by assumptions on durations of the different
health states. In separate CISNET analysis, we showed
that the median time from HPV acquisition to cancer
detection ranged from 18.0 to 26.0 years across the 4
models.9 Furthermore, we found that the short-term
reductions in cervical cancer deaths were different across
the models. This variation is mainly explained by differ-
ences in the effectiveness of treatment of detected cancers
(attributional fraction ranged from 10% to 38%), which
is the effect of the stage distributions of cancers detected
without screening (clinically) and with screening, as well
as the different survival probabilities per stage (Table 1).
Uncertainty on Unobservable Model
Inputs and Structures
There is limited knowledge of certain model inputs and
structures, because the underlying natural history
processes and parameters are unobservable in the real
world. First, the absolute test sensitivity of cytological
screening has never been examined in a randomized clini-
cal trial in a high-income country, and Pap characteris-
tics have been shown to be highly heterogeneous across
settings.10 Furthermore, since opportunistic cervical can-
cer screening was already introduced decades ago in
most countries, including the United States,11 informa-
tion on national cervical cancer incidence and mortality
before the introduction of screening is lacking in most
high-income countries. As a result, the effect of cervical
cancer screening on cervical cancer incidence and mortal-
ity is somewhat uncertain. Second, the preclinical dura-
tion for lesions that caused cervical cancer incident cases
and deaths (i.e., dwell times) cannot be observed using
epidemiological data. To estimate the preclinical dura-
tions, statistical models have been used. An evaluation
of British Columbia data12 showed that, after correcting
for lead time bias, a median duration of 15 years was
estimated from carcinoma in situ to invasive cancer.13
More recently, longer durations were estimated using
statistical models that included HPV.14,15 Third, the rate
of successful treatment and recurrence after treatment
for detected cervical lesions depends on the grade of the
lesion as well as the assumptions on loss to follow-up of
diagnosed women, sensitivity of diagnostic colposcopy,
and type of treatment modality. Most models assumed a
100% success rate for treatment of precancerous lesions,
but some assume a certain risk of recurrence. Survival
for invasive lesions is based on observed survival rates
from cancer registries (Table 1).
Because it is highly unlikely that new data on these 3
issues will become available, the way to handle uncertain-
ties in model estimates is to perform sensitivity analyses
to investigate the robustness of the results.
Limitations
Usually, models are characterized by describing the mod-
eling approach, model inputs, and assumptions. In this
study, we examined model outcomes to provide insight
into the mechanics of incidence and mortality predic-
tions. Several caveats should be considered in evaluating
this method. First, the effect of a single screen on cervical
cancer incidence and mortality is not the same as the
effect of repeated screening over decades, nor does it
capture a common context for evaluations in high-
income countries, which involves evaluating the impact
of changes to screening (e.g., the introduction of HPV
testing) in the context of long-established stable cytology
programs. The results in this study are therefore not
directly translatable to projections of the effects of a
Figure 3 Screening effects in 4 different models (refers to dark
gray area in Figure 2, the illustrative example): reduction in
clinical incidence (A) and incidence-based mortality (B) after one-
time realistic screening at age 45 years for the 4 different models.
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routine screening program on overall cervical cancer
incidence and mortality. Second, we chose to present the
MCLIR for a single screen at age 45 years because this is
approximately in the middle of the recommended cervi-
cal screening age range (25–65 years in many high-
income countries). However, the relative contributions
of the different origins may vary by age. Future work
evaluating the MCLIR scenarios at different ages might
provide insight into age-specific and between-model dif-
ferences in lesion inception, progression, and test charac-
teristics and the impact of these on cervical cancer
incidence and mortality.
Conclusion and Recommendation
CISNET collaborative modeling predictions are increas-
ingly used by policymakers to inform screening guide-
lines.16–19 How different models arrive at their
predictions of the harms and benefits of screening and
treatment may be perceived as opaque due to the com-
plexity of the models. A previous study proposed to
include the projected MCLIR as a prediction measure in
the description of screening models.2 A complete descrip-
tion of the structure and inputs of a model is still neces-
sary, but the knowledge about the models generated
with MCLIR analyses can help explain model differences
in predictions of screening effectiveness.
We showed that 4 independently developed CISNET
models showed similar long-term reductions in cervical
cancer incidence and mortality, but the relative contribu-
tions of the 3 possible factors varied across the models.
The differences among the 4 cervical cancer screening
models reflect genuine uncertainty on unobservable
model inputs and structures. Further sensitivity analyses
should be carried out to understand the impact of varia-
bility in modeling these uncertainties.
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